Table 5 Unadjusted OR for 30-day mortality by maximal KDIGO-UO.

From: Toward the standardization of big datasets of urine output for AKI analysis: a multicenter validation study

 

Patients, No. (%)

Mortality, No. (%)

Unadjusted OR

Adjusted Model1

OR (95% CI)

P value

OR (95% CI)

P value

MIMICdb

 No AKI

23,972 (0.52)

1,715 (0.07)

1 [reference]

 

1 [reference]

 

 Stage 1

11,262 (0.24)

1,336 (0.12)

1.75 (1.62, 1.88)

 < .001

1.58 (1.46–1.72)

 < 0.001

 Stage 2

8,991 (0.19)

1,826 (0.2)

3.31 (3.08, 3.55)

 < .001

2.94 (2.7–3.19)

 < 0.001

 Stage 3

2,119 (0.05)

775 (0.37)

7.48 (6.76, 8.28)

 < .001

5.24 (4.42–6.2)

 < 0.001

AUMCdb

 No AKI

10,235 (0.69)

605 (0.06)

1 [reference]

 

1 [reference]

 

 Stage 1

2,456 (0.16)

384 (0.16)

2.95 (2.57, 3.38)

 < .001

2.91 (2.53–3.36)

 < 0.001

 Stage 2

1,589 (0.11)

428 (0.27)

5.87 (5.11, 6.73)

 < .001

5.16 (4.42–6.03)

 < 0.001

 Stage 3

643 (0.04)

312 (0.49)

15 (12.6, 17.9)

 < .001

13.59 (10.49–17.62)

 < 0.001

  1. 1Model includes age, weight, gender and whether diagnosed on admission.
  2. All covariates in the adjusted model were significant.
Back to article page